SWOG clinical trial number
SWOG-9452 (INT-0159) (CALGB 9480)

A Phase III Study of Three Different Doses of Suramin (NSC# 34936) Administered with a Fixed Dosing Schedule in Patients with Advanced Prostate Cancer

Closed
Phase
Published
Abbreviated Title
A Phase III Study of Three Different Doses of Suramin (NSC# 34936) Administered with a Fixed Dosing Schedule in Patients with Advanced Prostate Cancer
Activated
10/01/1996
Closed
07/15/1998

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2002

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of Intergroup 0159, Cancer and Leukemia Group B 9480

EJ Small;S Halabi;MJ Ratain;G Rosner;W Stadler;D Palchak;E Marshall;R Rago;V Hars;G Wilding;D Petrylak;NJ Vogelzang Journal of Clinical Oncology 20(16):3369-3375

2000

Results of CALGB 9480, a phase III trial of 3 different doses of suramin for the treatment of hormone refractory prostate cancer (HRPC).

S Halabi;EJ Small;RH Ansari;G Wilding;DP Petrylak;DI Palchak;E Marshall;RP Rago;V Hars;NJ Vogelzang Proc of the American Society of Clinical Oncology 19:328a(#1291)

Other Clinical Trials

SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase